Intellia CRISPR-Cas9 platform creates gene insertion edits in vivo

Intellia Therapeutics Inc. (NASDAQ:NTLA) presented data at the European Society of Gene and Cell Therapy meeting in Lausanne, Switzerland, showing

Read the full 208 word article

User Sign In